Alberta residents with neovascular (wet) age-related macular degeneration (AMD), the leading cause of vision loss over the age of 50, have received a dose of good news with the decision by Alberta Health and Wellness to reimburse the innovative treatment Lucentis* (ranibizumab) on the Alberta Blue Cross insurance plan.
Highlights of May’s Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a new analysis of dietary factors and risks for age-related macular degeneration (AMD), and a landmark study on glaucoma treatment cost-effectiveness as linked to vision improvement and quality of life.
Highlights of May’s Ophthalmology, the journal of the American Academy of Ophthalmology, include a new analysis of dietary factors and risks for age-related macular degeneration (AMD), and a landmark study on glaucoma treatment cost-effectiveness as linked to vision improvement and quality of life.
With continued research, people with diabetes, Parkinson’s, spinal cord injuries, cancer, macular degeneration and heart or brain damage could have a higher quality of life or a lengthened life expectancy. …
This help the elderly to keep up healthy eyes and battles off macular degeneration. Macular retrogression is a very basic old age related eye disease that brings down the quality of life for many elderly. …
